Biogen BIIB Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Other | $223.2M+131% | $197.2M+139% | $157.1M— | $125.9M— | $96.7M— | |
| Total Revenue by Product | ||||||
| AVONEX | $691.9M-0.6% | $695.5M-1.7% | $703M-5.5% | $690.7M-11.4% | $695.8M-14.8% | |
| BENEPALI | $464M-1.6% | $453.2M-5.4% | $470.3M+1.8% | $466.5M+2.2% | $471.7M+5.2% | |
| BYOOVIZ | $23.5M-41.1% | $32.4M-11.5% | $33.8M-7.4% | $34.8M-1.7% | $39.9M+39.0% | |
| FAMPYRA | $1.1M-97.9% | $1.4M-98.0% | $14.7M-81.7% | $34.1M-57.8% | $52.8M-38.3% | |
| FLIXABI | $50M-14.5% | $52.6M-16.8% | $58.8M-7.8% | $59.7M-11.9% | $58.5M-21.8% | |
| FUMADERM And ADUHELM | $400K-95.7% | $2.1M-79.6% | $4.8M-52.0% | $6.9M-30.3% | $9.2M-13.2% | |
| IMRALDI | $192.4M-6.5% | $190.2M-10.7% | $197.7M-8.7% | $199.2M-8.2% | $205.7M-7.6% | |
| PLEGRIDY | $254.9M0.0% | $250.1M-4.0% | $252.9M-5.8% | $255.8M-6.2% | $254.9M-11.1% | |
| QALSODY | $103.9M+140% | $86.9M+168% | $73.6M+207% | $58.3M+299% | $43.3M+312% | |
| SKYCLARYS | $547.3M+27.8% | $520.5M+36.1% | $489.3M+45.5% | $458.7M+96.1% | $428.4M+220% | |
| SPINRAZA | $1.5B-9.6% | $1.55B-1.7% | $1.61B+3.0% | $1.62B-0.7% | $1.66B+1.0% | |
| TECFIDERA | $583.1M-36.5% | $679.7M-29.7% | $795.7M-19.1% | $860.3M-13.1% | $918.9M-7.4% | |
| TOFIDENCE | $600K-50.0% | $700K-36.4% | $200K-80.0% | $400K-50.0% | $1.2M— | |
| TYSABRI | $1.73B+3.6% | $1.67B-2.9% | $1.68B-4.6% | $1.66B-8.6% | $1.67B-9.3% | |
| VUMERITY | $787M+23.1% | $746.8M+18.9% | $742.3M+22.1% | $685.8M+11.5% | $639.3M+7.3% | |
| ZURZUVAE | $222.8M+155% | $195.1M+170% | $152.3M+199% | $119M+312% | $87.5M+525% | |
| After Second GAZYVA Threshold Date by Product | ||||||
| GAZYVA | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | |
| RITUXAN | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | |
| Share of non-controling interest recognized by Product | ||||||
| Alzheimer's collaboration revenue | 200%0.0pp | 200%0.0pp | 200%0.0pp | 200%0.0pp | 200%— | |
| Estimated additional payments upon achievement of development and commercial milestones by Product | ||||||
| Felzartamab And Izastobart/HIB210 | $2.56B— | $2.56B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Biogen break its business down?
- Biogen (BIIB) reports revenue by product across 2 parts — Contract manufacturing, royalty and other revenue and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Biogen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Biogen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
